An interventional study of Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education (AIRWISE) and Portable Air Cleaner (PAC) Control in Cardiovascular Diseases, Blood Pressure and Glycated Hemoglobin (HbA1c), sponsored by University of Montana. Not yet recruiting at 1 site in United States. Open to participants aged 55 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Montana · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Particulate matter air pollution is the leading environmental risk factor of cardiovascular disease and is increasing in the Western United States due to more frequent and severe wildfires. Older adults are particularly susceptible to both air pollution exposures and the development of cardiovascular disease, and the older adult population in the United States is rapidly growing. Given the converging threats of worsening air quality and an aging population, this clinical trial will evaluate a novel, multifaceted indoor air quality intervention to improve cardiovascular health outcomes among older adults in the wildfire-impacted state of Montana.
Particulate matter (PM) air pollution is the leading risk factor of global disease burden and the largest environmental risk factor for premature death and cardiovascular disease (CVD). Older adults are particularly susceptible to air pollution exposures and the development of CVD as they often have underlying health conditions. PM levels are rising in the Western United States (US) as wildfires have increased, with up to 50% of fine PM (PM2.5; particles \<2.5 µm in diameter) in some Western regions now attributed to wildfires. Recent research indicates there is often a substantial increase in indoor PM2.5 when outdoor PM2.5 increases, including during wildfire events. Improving indoor air quality is critically important as US adults spend 90% of their time indoors where air quality is impacted by numerous indoor and outdoor air pollution sources. New strategies are needed to improve indoor air quality and CVD health outcomes, particularly as the US population rapidly ages and the number of susceptible older adults grows. There is evidence that filtering indoor air with portable air cleaners (PACs) can result in short-term PM2.5 improvements. However, evidence is limited that PAC use meaningfully improves health, particularly in studies of longer duration. In response to this need, the investigators have developed a household indoor air quality intervention called AIRWISE (Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education). AIRWISE promotes sustained improvements in indoor air quality through education, behavioral cues, and equipment including PACs and PM2.5 sensors that display real-time data. In this project, the investigators will evaluate the AIRWISE intervention among older adults in the wildfire-impacted US state of Montana. In Aim 1, the investigators will conduct a randomized trial to test the efficacy of the AIRWISE intervention on PREVENT (Predicting Risk of CVD EVENTs), a validated CVD risk score. The central hypothesis is that PREVENT will be improved among older adults who use AIRWISE compared to controls who use only PACs. The rationale is that the AIRWISE intervention will promote sustained improvements in indoor air quality and CVD risk, a significant advance beyond PACs alone that are widely recommended yet have inconsistent benefits on long-term health. In Aim 2, the investigators will use Aim 1 data to determine associations between indoor PM2.5 concentrations and PREVENT. The investigators will use additional models between PM2.5 and the individual components of PREVENT as outcomes in order to determine which risk factors are most impacted by PM2.5 and inform underlying subclinical mechanisms. In Aim 3, the investigators will model the economic costs and benefits of indoor PM2.5 improvements and the AIRWISE intervention to inform policy-level action. With the converging threats of increasing air pollution due to wildfires and an aging US population, this project will contribute to identifying actionable strategies to improve indoor air quality and decrease CVD risk among older adults.
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's planned enrollment of 154 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →University of Montana is the lead sponsor of 28 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to the AIRWISE Intervention group will use AIRWISE in their homes for 12 months. The AIRWISE group will use two PACs to filter indoor air and two optical PM2.5 sensors with lights that change color in real time according to AQI. In addition, automated outdoor air quality alerts are sent via text and email when outdoor AQI goes above 75 (mid-point of the Moderate AQI category). Outdoor air quality will be referenced from the Environmental Protection Agency or PurpleAir monitor nearest to the participant's home. Based on the indoor and outdoor AQI levels, participants will reference a decision matrix and educational materials to make informed decisions on improving indoor air quality. Education and behavioral strategies are delivered through multiple approaches, including visual aids, handouts, videos, and a magnet with the decision matrix that can be placed in an accessible location in the home.
Behavioral: Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education (AIRWISE)
Participants randomized to the PAC Control group will use two PACs in their home without additional AIRWISE equipment/education. After randomization, they will be given instructions on study procedures and using the PAC units according to manufacturer recommendations. PAC Control group participants will not receive further education on air quality or recommendations on PAC use, nor will they receive additional equipment or outdoor AQI alerts. They will receive PurpleAir sensors without an AQI light that are for data collection purposes only, and they will not have access to the data throughout the study. Control participants will use and maintain the PACs at their own discretion. At the end of their participation, they will have the option of receiving the additional AIRWISE components.
Other: Portable Air Cleaner (PAC) Control
The AIRWISE intervention consists of a 3-pronged approach grounded in the Health Belief Model (HBM) to improve residential indoor air quality through education, equipment, and behavioral cues. To reinforce cues to action, AIRWISE uses alerts from air quality sensors, prompting timely behavioral responses. Specifically, indoor and outdoor air quality alerts act as behavioral cues to promote active engagement and reference a decision matrix with specific recommendations based indoor and outdoor air quality. Recommendations on the decision matrix include simple strategies to reduce air pollution exposures, including increasing use and fan speed of portable air cleaners, opening or closing windows to change ventilation, and changing activities such as physical activity, cooking, and cleaning. This integrated approach promotes sustained behavior change by aligning with all key HBM constructs.
Participants will use two PACs in their home according to manufacturer recommendations. PAC Control group participants will not receive further education on air quality or recommendations on PAC use, nor will they receive additional equipment or outdoor AQI alerts. Control participants will use and maintain the PACs at their own discretion.
Predicting Risk of CVD EVENTs (PREVENT) Score
Validated cardiovascular disease (CVD) risk score called Predicting Risk of CVD EVENTs (PREVENT). The score is a percentage ranging from 0 to 100 that indicates percentage risk of developing CVD, with higher scores indicating higher risk of developing CVD.
Time frame: 0, 6, 12 months
Life's Essential 8 (LE8) Score
Validated metric of cardiovascular health called Life's Essential 8 (LE8). The score ranges from 0 to 100, with higher scores indicating better cardiovascular health and lower risk of adverse cardiovascular outcomes.
Time frame: 0, 6, 12 months
Indoor PM2.5
Fine particulate matter (PM2.5), or particles that are less than 2.5 micrometers in aerodynamic diameter and a primary component of air pollution
Time frame: Continuous at 2-minute intervals
Indoor VOCs
Volatile Organic Compounds (VOCs), a component of air pollution
Time frame: Continuous at 2-minute intervals
Glycated hemoglobin
A measure of blood sugar levels measured through venous blood draw and used to calculate the primary PREVENT outcome
Time frame: 0, 6, 12 months
Estimated Glomerular Filtration Rate
A measure of kidney function measured through venous blood draw and used to calculate the primary PREVENT outcome
Time frame: 0, 6, 12 months
Total cholesterol
Measured through venous blood draw and used to calculate the primary PREVENT outcome
Time frame: 0, 6, 12 months
HDL cholesterol
High-density lipoprotein cholesterol measured through venous blood draw and used to calculate the primary PREVENT outcome
Time frame: 0, 6, 12 months
LDL cholesterol
Low-density lipoprotein cholesterol measured through venous blood draw and used to calculate the primary PREVENT outcome
Time frame: 0, 6, 12 months
CRP
C-reactive protein, a measure of inflammation measured through venous blood draw
Time frame: 0, 6, 12 months
ESR
Erythrocyte sedimentation rate, used as a measure of inflammation measured through venous blood draw
Time frame: 0, 6, 12 months
Uric acid
Used as a measure of inflammation measured through venous blood draw
Time frame: 0, 6, 12 months
CBC
Used as a measure of inflammation measured through venous blood draw
Time frame: 0, 6, 12 months
Systolic and diastolic blood pressure
A risk factor for CVD and used to calculate the primary PREVENT outcome
Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.
Health symptoms
Health symptoms will be reported in a questionnaire and used as a measure of quality of life. The questionnaire includes 6 questions and asks about recent illness and frequency of symptoms including eye irritation, blurred vision, wheezing, cough, throat irritation, difficulty breathing, excessive mucus, nose irritation, and headache.
Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.
Physical activity
A risk factor for cardiovascular health and used to calculate the secondary LE8 outcome. Physical activity will be reported in a questionnaire. The questionnaire includes 12 questions and asks about type, duration, and location of recent physical activities.
Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.
Sleep quality
A risk factor for cardiovascular health and used to calculate the secondary LE8 outcome. Sleep quality will be reported in a questionnaire. The questionnaire includes 9 questions and asks about duration, quality, barriers, and facilitators of sleep over the previous month.
Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.
Diet
A risk factor for cardiovascular health and used to calculate the secondary LE8 outcome. Diet will be reported in a questionnaire. The questionnaire includes 16 questions and asks about the recent frequency and amount of consuming 16 different types of foods.
Time frame: Measured at baseline, followed by once per month through study completion, for a total of 13 measurements.
BMI
A risk factor for cardiovascular health and used to calculate the secondary LE8 outcome
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Jul 2030, 39 months later.
Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 39 months is above that.
Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Apr 2027, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Montana